NOVO NORDISK A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.85 BRL | +8.86% |
|
+0.49% | +40.63% |
| Sales 2024 * | 289B 42.1B 217B 57.43B | Sales 2025 * | 349B 50.79B 262B 69.28B | Capitalization | 4,158B 605B 3,117B 825B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.18B 78.22B 20.7B | Net income 2025 * | 127B 18.42B 94.91B 25.12B | EV / Sales 2024 * | 14.4 x |
| Net Debt 2024 * | 13.34B 1.94B 10B 2.65B | Net cash position 2025 * | 12.63B 1.84B 9.47B 2.51B | EV / Sales 2025 * | 11.9 x |
| P/E ratio 2024 * |
40.4
x | P/E ratio 2025 * |
33.1
x | Employees | 66,015 |
| Yield 2024 * |
1.26% | Yield 2025 * |
1.52% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
| 1 day | +8.86% | ||
| 1 week | +0.49% | ||
| Current month | +4.58% | ||
| 1 month | +7.98% | ||
| 3 months | +13.93% | ||
| 6 months | +35.26% | ||
| Current year | +40.63% |
1 week
84.00
88.29
1 month
77.0088.29
Current year
61.7489.01
1 year
45.59102.61
3 years
30.55102.61
5 years
30.55102.61
10 years
30.55102.61
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 87.85 | +8.86% | 4 983 |
| 24-05-23 | 87.58 | +0.97% | 4,646 |
| 24-05-22 | 86.74 | -0.05% | 4,208 |
| 24-05-21 | 86.78 | +2.83% | 13,046 |
| 24-05-20 | 84.39 | -3.47% | 29,823 |
Delayed Quote Sao Paulo, May 24, 2024 at 02:26 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
937.4
DKK
Average target price
909.2
DKK
Spread / Average Target
-3.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.84% | 728B | |
| -5.87% | 360B | |
| +18.85% | 332B | |
| +1.06% | 279B | |
| +16.00% | 244B | |
| +8.09% | 207B | |
| -5.77% | 205B | |
| +6.30% | 164B | |
| -0.27% | 122B |
- Stock Market
- Equities
- NOVO B Stock
- N1VO34 Stock
